Lithium: A versatile tool for understanding renal physiology

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 9, 2013, Pages

  Kishore, Bellamkonda K ^a,b   Ecelbarger, Carolyn M ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

Aldosterone; Arginine vasopressin; Diabetes insipidus; Glycogen synthase kinase 3; Prostaglandins; Purinergic signaling

Indexed keywords

ALDOSTERONE; AQUAPORIN 2; CYCLOOXYGENASE 2; EPITHELIAL SODIUM CHANNEL; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; NEUROHYPOPHYSIS HORMONE; PROSTAGLANDIN E2; PROTEIN BCL 2; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; TRANSFORMING GROWTH FACTOR BETA1; VASOPRESSIN V2 RECEPTOR;

BIPOLAR DISORDER; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DEPRESSION; EXTRACELLULAR SPACE; GENE DELETION; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION RATE; GRAY MATTER; HUMAN; HYPERMAGNESEMIA; HYPERPARATHYROIDISM; KIDNEY CONCENTRATING CAPACITY; KIDNEY DEVELOPMENT; KIDNEY DISTAL TUBULE; KIDNEY FAILURE; KIDNEY FUNCTION; LITHIUM BLOOD LEVEL; MAJOR DEPRESSION; METABOLOMICS; NEPHROGENIC DIABETES INSIPIDUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POTASSIUM INTAKE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SODIUM ABSORPTION; SUBSTANCE ABUSE; UPREGULATION; WATER ABSORPTION;

EID: 84878540178     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00718.2012     Document Type: Review

References (130)

1. Ahearn EP, Chen P, Hertzberg M, Cornette M, Suvalsky L, Cooley-Olson D, Swanlund J, Eickoff J, Becker T, Krahn D. Suicide attempts in veterans with bipolar disorder during treatment with lithium, dival-proex, and atypical antipsychotics. J Affect Disord 145: 77-82, 2013.
2. Allen HM, Jackson RL, Winchester MD, Deck LV, Allon M. Indo-methacin in the treatment of lithium-induced nephrogenic diabetes insip-idus. Arch Intern Med 149: 1123-1126, 1989.
3. Baer L, Glassman AH, Kassir S. Negative sodium balance in lithium carbonate toxicity. Evidence of mineralocorticoid blockade. Arch Gen Psychiatry 29: 823-827, 1973.
4. Baldenssarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr 11: 465-471, 2006.
5. Bedford JJ, Leader JP, Jing R, Walker LJ, Klein JD, Sands JM, and Walker RJ. Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 294: F812-F820, 2008.
6. Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, Walker RJ. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 3: 1324-1331, 2008.
7. Boer WH, Fransen R, Shirley DG, Walter SJ, Boer P, Koomans HA. Evaluation of the lithium clearance method: direct analysis of tubular lithium handling by micropuncture. Kidney Int 47: 1023-1030, 1995.
8. Bostanjoglo M, Reeves WB, Reilly RF, Velazquez H, Robertson N, Litwack G, Morsing P, Dorup J, Bachmann S, Ellison DH, Boston-joglo M. 11Beta-hydroxysteroid dehydrogenase, mineralocorticoid receptor, and thiazide-sensitive Na-Cl cotransporter expression by distal tubules. J Am Soc Nephrol 9: 1347-1358, 1998.
9. Brash AR. Arachidonic acid as a bioactive molecule. J Clin Invest 107: 1339-1345, 2001.
10. Budziszewska B, Lason W. Pharmacological modulation of glucocor-ticoid and mineralocorticoid receptors in the rat central nervous system. Pol J Pharmacol 46: 97-102, 1994.
11. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 2: 349-352, 1949.
12. Camins A, Verdaguer E, Junyent F, Yeste-Velasco M, Pelegri C, Vilaplana J, Pallas M. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther 15: 333-344, 2009.
13. Chandragiri SS, Pasol E, Gallagher RM. Lithium ACE inhibitors, NSAIDs, and verapamil. A possible fatal combination. Psychosomatics 39: 281-282, 1998.
14. Chen L, Williams SK, Schafer JA. Differences in synergistic actions of vasopressin and deoxycorticosterone in rat and rabbit CCD. Am J Physiol Renal Fluid Electrolyte Physiol 259: F147-F156, 1990.
15. Christensen BM, Kim YH, Kwon TH, Nielsen S. Lithium-treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 291: F39-F48, 2006.
16. Christensen BM, Marples D, Kim YH, Wang W, Frokiaer J, Nielsen S. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 286: C952-C964, 2004.
17. Christensen BM, Zuber AM, Loffing J, Stehle JC, Deen PM, Rossier BC, Hummler E. AlphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol 22: 253-261, 2011.
18. Chuang DM. Neuroprotective and neurotropic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16:83-90, 2004.
19. Ecelbarger CA. Lithium treatment and remodeling of the collecting duct. Am J Physiol Renal Physiol 291: F37-F38, 2006.
20. Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, Verbalis JG, Knepper MA. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol 279: F46-F53, 2000.
21. Ecelbarger CA, Kim GH, Wade JB, Knepper MA. Regulation of the abundance of renal sodium transporters and channels by vasopressin. Exp Nephrol 171: 227-234, 2001.
22. El-Mallakh RS, Jefferson JW. Prethymoleptic use of lithium. Am J Psychiatry 156: 1, 1999.
23. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 29: 172-191, 1995.
24. Fernández-Llama P, Ecelbarger CA, Ware JA, Andrews P, Lee AJ, Turner R, Nielsen S, Knepper MA. Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle's loop. Am J Physiol Renal Physiol 277: F219-F226, 1999.
25. Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 284: 9643-9647, 2009.
26. Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF. Does lithium prevent Alzheimer's disease? Drugs Aging 29: 335-342, 2012.
27. Fritzpatrick FA, Soberman R. Regulated formation of eicosanoids. J Clin Invest 107: 1347-1351, 2001.
28. Gao C, Holscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 23: 1-11, 2012.
29. Gitlin M. Lithium and the kidney: an update review. Drug Saf 20: 231-243, 1994.
30. Gonzalez R, Bernstein I, Suppes T. An investigation of water lithium concentrations and rates of violent acts in 11 Texas counties: can an association be easily shown? J Clin Psychiatry 69: 325-326, 2008.
31. Goodwin FK, Ghaemi NS. The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe. Aust NZ J Psychiatry 33: 554-564, 1999.
32. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30: 1223-1237, 2005.
33. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9: 734-755, 2004.
34. Grünfeld JP, Rossier BC Lithium nephrotoxicity revisited. Nat Rev Nephrol 5: 270-276, 2009.
35. Han JS, Maeda Y, Ecelbarger C, Knepper MA. Vasopressin-indepen-dent regulation of collecting duct water permeability. Am J Physiol Renal Fluid Electrolyte Physiol 266: F139-F146, 1994.
36. Handler J. Lithium and antihypertensive medication: a potentially dangerous interaction. J Clin Hypertens (Greenwich) 11: 738-742, 2009.
37. Hansen HE, Hestbech J, Sorensen JL, Norgaard K, Heilskov J, Amdisen A. Chronic interstitial nephropathy in patients on long-term lithium treatment. Q J Med 48: 577-591, 1979.
38. + transport in rat CCD. Kidney Int Suppl 57: S35-S41, 1996.
39. Hensen J, Haenett M, Gross P. Lithium-induced polyuria and renal vasopressin receptor density. Nephrol Dial Transplant 11: 622-627, 1996.
40. Hirschowitz J, Kolevzon A, Garakami A. The pharmacological treatment of bipolar disorder: the question of modern advances. Harv Rev Psychiastry 18: 266-278, 2010.
41. Hoge CW, Castro CA, Messer SC, McGurk D, Cottling DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. New Engl J Med 351: 13-22, 2004.
42. Howard C, Tao S, Yang HC, Fogo AB, Woodgett JR, Harris RC, Rao R. Specific deletion of glycogen synthase kinase-3beta in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney Int 82: 1000-1009, 2012.
43. Hwang G-S, Yang J-Y, Ryu DH, Kwon T-H. Metabolic profiling of kidney and urine in rats with lithium-induced nephrogenic diabetes insipidus by 1H-NMR-based metabonomics. Am J Physiol Renal Physiol 298: F461-F470, 2010.
44. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 61: 47-51, 2000.
45. Janowsky DS, Soares J, Hatch JP, Zunta-Soares G, Hu Q, Davis JM. Lithium effect on renal glomerular function in individuals with intellectual disability. J Clin Psychopharmacol 29: 296-299, 2009.
46. Jia Z, Wang H, Yang T. Mice lacking mPGES-1 are resistant to lithium-induced polyuria. Am J Physiol Renal Physiol 297: F1689-F1696, 2009.
47. Kim G-H, Choi NK, Jung J-Y, Song J-H, Lee CH, Kang CM, Knepper MA. Treating lithium-induced nephrogenic diabetes insipidus with COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2. Am J Physiol Renal Physiol 294: F702-F709, 2008.
48. Kim Y-H, Kwon T-H, Christensen BM, Nielsen J, Wall SM, Madsen KM, Frøkiær J, Nielsen S. Altered expression of renal acid-base transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 285: F1244-F1257, 2003.
49. Kirschner MS, Marincola E, Teisberg EO. The role of biomedical research in health care reform. Science 266: 49-51, 1994.
50. Kishore BK, Nelson RD, Miller RL, Carlson NG, Kohan DE. P2Y2 receptors and water transport in the kidney. Puriner Signal 5: 491-499, 2009.
51. Kjaersgaard G, Madsen K, Marcussen N, Christensen S, Walter S, Jensen BL. Tissue injury after lithium treatment in human and rat postnatal kidney involves glycogen synthase kinase-3 fj-positive epithelium. Am J Physiol Renal Physiol 302: F455-F465, 2012.
52. Klein JD, Bount MA, Sands JM. Molecular mechanisms of urea transport in health and disease. Pflügers Arch 464: 561-572, 2012.
53. Klein JD, Gunn RB, Roberts BR, Sands JM. Down-regulation of urea transporters in the renal inner medulla of lithium-fed rats. Kidney Int 61: 995-1002, 2002.
54. Kortenoevern ML, Li Y, Shaw S, Gaeggeler H-P, Rossier BC, Wetzels JF, Deen PM. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 76: 44-53, 2009.
55. Kortenoeven ML, Schweer H, Cox R, Wetzel JF, Deen PM. Lithium reduces aquaporin-2 transcription independent of prostaglandins. Am J Physiol Cell Physiol 302: C131-C140, 2012.
56. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frøkiær J, Nielsen S. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 288: F1053-F1068, 2005.
57. Kuure S, Possueva A, Jakobson M, Sainio K, Sariola H. Glycogen synthase kinase-3 inactivation and stabilization of fj-catenin induce nephron differentiation in isolated mouse and rat kidney mesenchymes. J Am Soc Nephrol 18: 1130-1139, 2007.
58. + transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 279: F552-F564, 2000.
59. Laursen UH, Pihakaski-Maunsbach K, Kwon TH, Ostergaard Jensen E, Nielsen S, Maunsbach AB. Changes of rat kidney AQP2 and Na,K-ATPase mRNA expression in lithium-induced nephrogenic diabetes insipidus. Nephron Exp Nephrol 97: e1-e16, 2004.
60. Laville M. Loop diuretics and angiotensin-converting enzyme inhibitors increased risk for hospitalization for lithium toxicity. ACP J Club 142: 25, 2005.
61. Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: What do we know? J Affect Disord 146: 151-157, 2013.
62. Li Y, Shaw S, Kamsteeg E-J, Vanderwalle A, Deen PM. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol 17: 1063-1072, 2006.
63. Loffing J, Zecevic M, Feraille E, Kaissling B, Asher C, Rossier BC, Firestone GL, Pearce D, Verrey F. Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. Am J Physiol Renal Physiol 280: F675-F682, 2001.
64. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46: 929-940, 1999.
65. Marples D, Christensen S, Christensen EL, Ottosen PD, Nielsen S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 95: 1838-1845, 1995.
66. Masilamani S, Kim GH, Mitchell C, Wade JB. Knepper MA. Aldo-sterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest 104: R19-R23, 1999.
67. Mason BL, Pariante CM. The effects of antidepressants on the hypo-thalamic-pituitary-adrenal axis. Drug News Perspect 19: 603-608, 2006.
68. McCann SM, Daly J, Kelly CB. The impact of long-term lithium treatment on renal function in an outpatient population. Ulster Med J77: 102-105, 2008.
69. Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Mora ME, Browne MO, Ono Y, Posada-Villa J, Sagar R, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68: 241-251, 2011.
70. Mitchell PB. On the 50th anniversary of John Cade's discovery of the anti-manic effect of lithium. Aust NZ J Psychiatry 33: 623-628, 1999.
71. Mitchell PB, Mahil GS. Emerging drugs for bipolar disorders. Expert Opin Emerg Drugs 11: 621-634, 2006.
72. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet 356: 1241-1242, 2000.
73. Murray MD, Brater DC. Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu Rev Pharmacol Toxicol 32: 435-465, 1993.
74. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci USA 105: 3634-3639, 2008.
75. Nielsen J, Kwon TH, Frøkiær J, Knepper MA, Nielsen S. Lithium-induced NDI in rats is associated with loss of a-ENaC regulation by aldosterone in CCD. Am J Physiol Renal Physiol 290: F1222-F1233, 2006.
76. Nielsen J, Kwon TH, Praetorius J, Frøkiær J, Knepper MA, Nielsen S. Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus. Am J Physiol Renal Physiol 290: F438-F449, 2006.
77. Nielsen J, Kwon TH, Praetorius J, Kim YH, Frøkiær J, Knepper MA, Nielsen S. Segment-specific ENaC downregulation in kidney of rats with lithium-induced NDI. Am J Physiol Renal Physiol 285: F1198-F1209, 2003.
78. Nivoli AM, Murru A, Vieta E. Lithium: still a corner stone in the long-term treatment in bipolar disorder? Neuropsychobiology 62: 27-35, 2010.
79. Oghami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br J Psychiatry 194: 464-465, 2009.
80. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol 11: 887-895, 1999.
81. Olesen ET, Fenton RA. Is there a role for PGE2 in urinary concentration? J Am Soc Nephrol 24: 169-178, 2013.
82. Olesen ET, Rützler MR, Moeller HB, Prætorius HA, Fenton RA. Vasopressin-independent targeting of aquaporin-2 by selective E-pros-tanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 108: 12949-12954, 2011.
83. Padfield PL, Morton JJ, Lindop G, Timbury GC. Lithium induced nephrogenic diabetes insipidus: changes in plasma vasopressin and angiotensin II. Clin Nephrol 3: 220-224, 1975.
84. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phos-phatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932, 1998.
85. Park EY, Kim WY, Kim YM, Lee JH, Han KH, Weiner ID, Kim J. Proposed mechanism in the change of cellular composition in the outer medullary collecting duct during potassium homeostasis. Histol Histo-pathol 27: 1559-1577, 2012.
86. Pedersen EB, Amdisen A, Darling S. Plasma aldosterone and magnesium in serum and urine during lithium treatment. Int Pharmacopsychiatry 12: 80-85, 1977.
87. Perez GO, Oster JR, Vaamonde CA. Incomplete syndrome of renal tubular acidosis induced by lithium carbonate. J Lab Clin Med 86: 386-394, 1975.
88. Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclo-oxygenase-2 inhibitors refecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 64: 1328-1334, 2003.
89. Presen C, Fakhouri F, Noel LH, Stengel B, Even C, Kreis H, Mignon F, Grünfeld JP. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 64: 585-592, 2003.
90. Quiroz JA, Machado-Viera R, Zarate CA Jr. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62: 50-60, 2010.
91. Radin M.J, Yu M-J, Stoedkilde L, Miller RL, Hoffert JD, Frokiær J, Pistkun T, Knepper MA. Aquaporin-2 regulation in health and disease. Vet Clin Pathol 41: 455-470, 2012.
92. Raja M. Lithium and kidney, 60 years later. Curr Drug Saf6: 291-303, 2011.
93. Rao R. Glycogen synthase kinase-3 regulation of urinary concentrating ability. Curr Opin Nephrol Hypertens 21: 541-546, 2012.
94. Rao R, Patel S, Hao C, Woodgett J, Harris R. GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity. J Am Soc Nephrol 21: 428-437, 2010.
95. Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD, Hao CM. Lithium treatment inhibits renal GSK-3 activity and promotes cycloox-ygenase 2-dependent polyuria. Am J Physiol Renal Physiol 288: F642-F649, 2005.
96. Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults-a systematic review. J Geriatr Psychiatry Neurol 25:51-61, 2012.
97. Rojek A, Nielsen J, Brooks HL, Gong H, Kim YH, Kwon TH, Frøkiær J, Nielsen S. Altered expression of selected genes in kidney of rats with lithium-induced NDI. Am J Physiol Renal Physiol 288: F1276-F1289, 2005.
98. +, and urea transport in inner medullary collecting duct. Am J Physiol Renal Physiol 279: F294-F301, 2000.
99. Rowe MK, Chuang DM. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 18: 1-18, 2004.
100. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280: 720-725, 2001.
101. Sands JM, Bichet DG. Nephrogenic diabetes insipidus. Ann Intern Med 144: 186-194, 2006.
102. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170: 1101-1111, 2005.
103. Sassi RB, Nicoletti M, Brambilla P, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 329: 243-245, 2002.
104. Schwiebert EM, Kishore BK. Extracellular nucleotide signaling along the renal epithelium. Am J Physiol Renal Physiol 280: F945-F963, 2001.
105. Semba J, Watanabe H, Suhara T, Akanuma N. Chronic lithium chloride injection increases glucocorticoid receptor but not mineralocor-ticoid receptor mRNA expression in rat brain. Neurosci Res 38: 313-319, 2000.
106. Schrauzer GN. Lithium: occurrence, dietary intakes, nutritional essentiality. J Am Coll Nutr 21: 14-21, 2002.
107. Steiner M, Phillips MI. Renal tubular vasopressin receptors downregu-lated by dehydration. Am J Physiol Cell Physiol 254: C404-C410, 1988.
108. Sugawara M, Hashimot K, Ota Z. Involvement of prostaglandin E2, cAMP, and vasopressin in lithium-induced polyuria. Am J Physiol Regul Integr Comp Physiol 254: R863-R869, 1988.
109. Sun R, Carlson NG, Hemmert AC, Kishore BK. P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol 289: F585-F592, 2005.
110. Sundin J, Fear NT, Iversen A, Rona RJ, Wessley S. PTSD after deployment to Iraq: conflicting rates, conflicting claims. Psychol Med 40: 367-382, 2010.
111. Terada Y, Tomita K, Nonoguchi H, Yang T, Marumo F. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest 92: 2339-2345, 1993.
112. Thomsen K, Bak M, Shirley DG. Chronic lithium treatment inhibits amiloride-sensitive sodium transport in the rat distal nephron. J Pharmacol Exp Ther 289: 443-447, 1999.
113. Transbol I, Christiansen C, Baastrup PC, Nielsen MD, Giese J. Endocrine effects of lithium. III. Hypermagnesaemia and activation of the renin-aldosterone system. Acta Endocrinol (Copenh) 88: 619-624, 1978.
114. Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord 126: 436-440, 2010.
115. Trepiccione F, Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol 16: S43-S48, 2010.
116. Vallon V. P2 receptors in the regulation of renal transport mechanisms. Am J Physiol Renal Physiol 294: F10-F27, 2008.
117. Wada A. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 14: 1558-1570, 2009.
118. Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 99: 307-321, 2005.
119. Walker RJ, Leader JP, Bedford JJ, Gobe GC, Davis G, Vos FE, Dejong S. Schollum JB. Chronic interstitial fibrosis in the rat kidney induced by long-term (6-mo) exposure to lithium. Am J Physiol Renal Physiol 304: F300-F307, 2013.
120. Weinstock RS, Moses AM. Desmopressin and indomethacin therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate. South Med J 83: 1475-1477, 1990.
121. Welch BD, Carlson NG, Shi H, Myatt L, Kishore BK. P2Y2 receptor-stimulated release of prostaglandin E2 by rat inner medullary collecting duct preparations. Am J Physiol Renal Physiol 285: F711-F721, 2003.
122. Woodgett JR. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord 3: 281-290, 2003.
123. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 35: 161-168, 2010.
124. Xu J, Scholz A, Rosch N, Blume A, Unger T, Kreutz R, Culman J, Gohlke P. Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats. J Hypertens 23: 2277-2285, 2005.
125. Young W. Review of lithium effects on brain and blood. Cell Transplant 18: 951-975, 2009.
126. Zarse K, Terao T, Tian J, Iwata N, Ishii N, Ristow M. Low-dose lithium uptake promotes longevity in humans and metazoans. Eur J Nutr 50: 387-389, 2011.
127. Zelenina M, Christensen BM, Palmer J, Narin AC, Nielsen S, Aperia A. Prostaglandin E2 interaction with AVP: effect of AQP2 phosphory-lation and distribution. Am J Physiol Renal Physiol 278: F338-F394, 2000.
128. Zhang Y, Kohan DE, Nelson RD, Carlson NG, Kishore BK. Potential involvement of P2Y2 receptor in diuresis of postobstructive uroapthy in rats. Am J Physiol Renal Physiol 298: F634-F642, 2010.
129. Zhang Y, Nelson RD, Carlson NG, Kamerath CD, Kohan DE, Kishore BK. Potential role of purinergic signaling in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 296: F1194-F1201, 2009.
130. Zhang Y, Pop IL, Carlson NG, Kishore BK. Genetic deletion of P2Y2 receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE2 signaling. Am J Physiol Renal Physiol 302: F70-F77, 2012.